Skip to main content

Peer Review reports

From: Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

Original Submission
6 Jun 2024 Submitted Original manuscript
7 Jun 2024 Author responded Author comments - Feride Yilmaz
7 Jun 2024 Author responded Author comments - Feride Yilmaz
Resubmission - Version 2
7 Jun 2024 Submitted Manuscript version 2
19 Jun 2024 Reviewed Reviewer Report - Claudio Dazzi
2 Aug 2024 Reviewed Reviewer Report
16 Aug 2024 Reviewed Reviewer Report
5 Sep 2024 Author responded Author comments - Feride Yilmaz
Resubmission - Version 3
5 Sep 2024 Submitted Manuscript version 3
6 Sep 2024 Author responded Author comments - Feride Yilmaz
Resubmission - Version 4
6 Sep 2024 Submitted Manuscript version 4
9 Sep 2024 Author responded Author comments - Feride Yilmaz
Resubmission - Version 5
9 Sep 2024 Submitted Manuscript version 5
10 Sep 2024 Author responded Author comments - Feride Yilmaz
Resubmission - Version 6
10 Sep 2024 Submitted Manuscript version 6
Publishing
11 Sep 2024 Editorially accepted
1 Oct 2024 Article published 10.1186/s12885-024-12935-x

You can find further information about peer review here.

Back to article page